JC4 Stock Overview
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Universal Ibogaine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0045 |
| 52 Week High | CA$0.025 |
| 52 Week Low | CA$0.0005 |
| Beta | 4.74 |
| 1 Month Change | -43.75% |
| 3 Month Change | 800.00% |
| 1 Year Change | 200.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| JC4 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.4% | 1.1% |
| 1Y | 200.0% | -0.9% | 6.5% |
Return vs Industry: JC4 exceeded the German Healthcare industry which returned -1.1% over the past year.
Return vs Market: JC4 exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| JC4 volatility | |
|---|---|
| JC4 Average Weekly Movement | 331.9% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: JC4's share price has been volatile over the past 3 months.
Volatility Over Time: JC4's weekly volatility has decreased from 535% to 332% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Nick Karos | universalibogaine.com |
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. The company is headquartered in Calgary, Canada.
Universal Ibogaine Inc. Fundamentals Summary
| JC4 fundamental statistics | |
|---|---|
| Market cap | €2.96m |
| Earnings (TTM) | -€802.71k |
| Revenue (TTM) | €1.51m |
2.0x
P/S Ratio-3.7x
P/E RatioIs JC4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JC4 income statement (TTM) | |
|---|---|
| Revenue | CA$2.22m |
| Cost of Revenue | CA$1.58m |
| Gross Profit | CA$640.33k |
| Other Expenses | CA$1.83m |
| Earnings | -CA$1.19m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0041 |
| Gross Margin | 28.79% |
| Net Profit Margin | -53.30% |
| Debt/Equity Ratio | 153.6% |
How did JC4 perform over the long term?
See historical performance and comparison